-
Something wrong with this record ?
Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex
JMA. Kusters, B. Diergaarde, A. Ness, MF. Schim van der Loeff, JCM. Heijne, L. Schroeder, K. Hueniken, JD. McKay, GJ. Macfarlane, P. Lagiou, A. Lagiou, J. Polesel, A. Agudo, L. Alemany, W. Ahrens, CM. Healy, DI. Conway, M. Robinson, C. Canova, I....
Language English Country United States
Document type Journal Article
Grant support
R01 DE025712
NIDCR NIH HHS - United States
P30CA047904
NIH HHS - United States
P50CA097190
NIH HHS - United States
R01 DE025712
NIDCR NIH HHS - United States
P30CA047904
NIH HHS - United States
P50CA097190
NIH HHS - United States
PubMed
37694289
DOI
10.1002/ijc.34710
Knihovny.cz E-resources
- MeSH
- Papillomavirus Infections * MeSH
- Humans MeSH
- Human Papillomavirus Viruses MeSH
- Human papillomavirus 16 MeSH
- Head and Neck Neoplasms * diagnosis MeSH
- Oropharyngeal Neoplasms * MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
A growing proportion of head and neck cancer (HNC), especially oropharyngeal cancer (OPC), is caused by human papillomavirus (HPV). There are several markers for HPV-driven HNC, one being HPV early antigen serology. We aimed to investigate the diagnostic accuracy of HPV serology and its performance across patient characteristics. Data from the VOYAGER consortium was used, which comprises five studies on HNC from North America and Europe. Diagnostic accuracy, that is, sensitivity, specificity, Cohen's kappa and correctly classified proportions of HPV16 E6 serology, was assessed for OPC and other HNC using p16INK4a immunohistochemistry (p16), HPV in situ hybridization (ISH) and HPV PCR as reference methods. Stratified analyses were performed for variables including age, sex, smoking and alcohol use, to test the robustness of diagnostic accuracy. A risk-factor analysis based on serology was conducted, comparing HPV-driven to non-HPV-driven OPC. Overall, HPV serology had a sensitivity of 86.8% (95% CI 85.1-88.3) and specificity of 91.2% (95% CI 88.6-93.4) for HPV-driven OPC using p16 as a reference method. In stratified analyses, diagnostic accuracy remained consistent across sex and different age groups. Sensitivity was lower for heavy smokers (77.7%), OPC without lymph node involvement (74.4%) and the ARCAGE study (66.7%), while specificity decreased for cases with <10 pack-years (72.1%). The risk-factor model included study, year of diagnosis, age, sex, BMI, alcohol use, pack-years, TNM-T and TNM-N stage. HPV serology is a robust biomarker for HPV-driven OPC, and its diagnostic accuracy is independent of age and sex. Future research is suggested on the influence of smoking on HPV antibody levels.
Bristol Dental School University of Bristol Bristol UK
Centro di Riferimento Oncologico di Aviano IRCCS Aviano Italy
Dalla Lana School of Public Health University of Toronto Toronto Canada
Department of Cellular Pathology Royal Victoria Infirmary Newcastle upon Tyne UK
Department of Infectious Diseases Public Health Service of Amsterdam Amsterdam The Netherlands
Genomic Epidemiology Group International Agency for Research on Cancer Lyon France
Infections and Cancer Epidemiology German Cancer Research Center Heidelberg Germany
Institute for Infection and Immunity Amsterdam UMC Amsterdam The Netherlands
NIHR Bristol Biomedical Research Centre Weston NHS Foundation Trust University of Bristol Bristol UK
Reference Center for Epidemiology and Cancer Prevention Piemonte Italy
School of Medicine Dentistry and Nursing University of Glasgow Dublin UK
School of Medicine National and Kapodistrian University of Athens Athens Greece
School of Public Health University of West Attica Athens Greece
Trinity College School of Dental Science Dublin Ireland
Unit of Nutrition and Cancer Catalan Institute of Oncology ICO L'Hospitalet de Llobregat Spain
University of Bremen Bremen Germany
University of North Carolina Lineberger Comprehensive Cancer Center Chapel Hill North Carolina USA
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc24000095
- 003
- CZ-PrNML
- 005
- 20240213092948.0
- 007
- ta
- 008
- 240109s2024 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1002/ijc.34710 $2 doi
- 035 __
- $a (PubMed)37694289
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Kusters, Johannes M A $u Centre for Infectious Diseases Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands $u Institute for Infection and Immunity (AII), Amsterdam UMC, Amsterdam, The Netherlands $u Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany $1 https://orcid.org/0000000225091661
- 245 10
- $a Diagnostic accuracy of HPV16 early antigen serology for HPV-driven oropharyngeal cancer is independent of age and sex / $c JMA. Kusters, B. Diergaarde, A. Ness, MF. Schim van der Loeff, JCM. Heijne, L. Schroeder, K. Hueniken, JD. McKay, GJ. Macfarlane, P. Lagiou, A. Lagiou, J. Polesel, A. Agudo, L. Alemany, W. Ahrens, CM. Healy, DI. Conway, M. Robinson, C. Canova, I. Holcátová, L. Richiardi, A. Znaor, M. Pring, S. Thomas, DN. Hayes, G. Liu, RJ. Hung, P. Brennan, AF. Olshan, S. Virani, T. Waterboer
- 520 9_
- $a A growing proportion of head and neck cancer (HNC), especially oropharyngeal cancer (OPC), is caused by human papillomavirus (HPV). There are several markers for HPV-driven HNC, one being HPV early antigen serology. We aimed to investigate the diagnostic accuracy of HPV serology and its performance across patient characteristics. Data from the VOYAGER consortium was used, which comprises five studies on HNC from North America and Europe. Diagnostic accuracy, that is, sensitivity, specificity, Cohen's kappa and correctly classified proportions of HPV16 E6 serology, was assessed for OPC and other HNC using p16INK4a immunohistochemistry (p16), HPV in situ hybridization (ISH) and HPV PCR as reference methods. Stratified analyses were performed for variables including age, sex, smoking and alcohol use, to test the robustness of diagnostic accuracy. A risk-factor analysis based on serology was conducted, comparing HPV-driven to non-HPV-driven OPC. Overall, HPV serology had a sensitivity of 86.8% (95% CI 85.1-88.3) and specificity of 91.2% (95% CI 88.6-93.4) for HPV-driven OPC using p16 as a reference method. In stratified analyses, diagnostic accuracy remained consistent across sex and different age groups. Sensitivity was lower for heavy smokers (77.7%), OPC without lymph node involvement (74.4%) and the ARCAGE study (66.7%), while specificity decreased for cases with <10 pack-years (72.1%). The risk-factor model included study, year of diagnosis, age, sex, BMI, alcohol use, pack-years, TNM-T and TNM-N stage. HPV serology is a robust biomarker for HPV-driven OPC, and its diagnostic accuracy is independent of age and sex. Future research is suggested on the influence of smoking on HPV antibody levels.
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a lidský papilomavirus 16 $7 D052162
- 650 _2
- $a lidské papilomaviry $7 D000094302
- 650 12
- $a infekce papilomavirem $7 D030361
- 650 12
- $a nádory orofaryngu $7 D009959
- 650 12
- $a nádory hlavy a krku $x diagnóza $7 D006258
- 655 _2
- $a časopisecké články $7 D016428
- 700 1_
- $a Diergaarde, Brenda $u School of Public Health, University of Pittsburgh and UPMC Hillman Cancer Centre, Pittsburgh, Pennsylvania, USA
- 700 1_
- $a Ness, Andrew $u NIHR Bristol Biomedical Research Centre, Weston NHS Foundation Trust, University of Bristol, Bristol, UK $u Bristol Dental School, University of Bristol, Bristol, UK
- 700 1_
- $a Schim van der Loeff, Maarten F $u Institute for Infection and Immunity (AII), Amsterdam UMC, Amsterdam, The Netherlands $u Department of Infectious Diseases, Public Health Service of Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Heijne, Janneke C M $u Centre for Infectious Diseases Control, National Institute for Public Health and the Environment, Bilthoven, The Netherlands $u Department of Social Medicine, Care and Public Health Research Institute (CAPHRI), Maastricht University, Maastricht, The Netherlands
- 700 1_
- $a Schroeder, Lea $u Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- 700 1_
- $a Hueniken, Katrina $u Princess Margaret Cancer Centre, Temerty School of Medicine, University of Toronto, Toronto, Ontario, Canada
- 700 1_
- $a McKay, James D $u Genomic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- 700 1_
- $a Macfarlane, Gary J $u Epidemiology Group, School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Aberdeen, UK
- 700 1_
- $a Lagiou, Pagona $u School of Medicine, National and Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Lagiou, Areti $u School of Public Health, University of West Attica, Athens, Greece
- 700 1_
- $a Polesel, Jerry $u Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy $1 https://orcid.org/0000000193811520
- 700 1_
- $a Agudo, Antonio $u Unit of Nutrition and Cancer, Catalan Institute of Oncology - ICO, L'Hospitalet de Llobregat, Spain $u Nutrition and Cancer Group, Epidemiology Public Health Cancer Prevention and Palliative Care Program, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Spain
- 700 1_
- $a Alemany, Laia $u Nutrition and Cancer Group, Epidemiology Public Health Cancer Prevention and Palliative Care Program, Bellvitge Biomedical Research Institute - IDIBELL, L'Hospitalet de Llobregat, Spain $u Centro de Investigación Biomédica en Red: Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, Madrid, Spain
- 700 1_
- $a Ahrens, Wolfgang $u University of Bremen, Bremen, Germany
- 700 1_
- $a Healy, Claire M $u Trinity College School of Dental Science, Dublin, Ireland
- 700 1_
- $a Conway, David I $u School of Medicine, Dentistry, and Nursing, University of Glasgow, Dublin, UK $1 https://orcid.org/0000000177624063
- 700 1_
- $a Robinson, Max $u Department of Cellular Pathology, Royal Victoria Infirmary, Newcastle upon Tyne, UK
- 700 1_
- $a Canova, Cristina $u University of Padova, Padova, Italy
- 700 1_
- $a Holcátová, Ivana $u First Faculty of Medicine, Institute of Hygiene and Epidemiology, Charles University, Prague, Czech Republic
- 700 1_
- $a Richiardi, Lorenzo $u Reference Center for Epidemiology and Cancer Prevention, Piemonte, Italy
- 700 1_
- $a Znaor, Ariana $u Genomic Epidemiology Group, International Agency for Research on Cancer, Lyon, France $1 https://orcid.org/0000000258494782
- 700 1_
- $a Pring, Miranda $u Bristol Dental School, University of Bristol, Bristol, UK
- 700 1_
- $a Thomas, Steve $u Bristol Dental School, University of Bristol, Bristol, UK
- 700 1_
- $a Hayes, D Neil $u Division of Medical Oncology and Center for Cancer Research, University of Tennessee Health Science Center, Memphis, Tennessee, USA $1 https://orcid.org/0000000162037771
- 700 1_
- $a Liu, Geoffrey $u Princess Margaret Cancer Centre, Temerty School of Medicine, University of Toronto, Toronto, Ontario, Canada $u Dalla Lana School of Public Health, University of Toronto, Toronto, Canada
- 700 1_
- $a Hung, Rayjean J $u Dalla Lana School of Public Health, University of Toronto, Toronto, Canada $u Prosserman Centre for Population Health Research, Lunenfeld-Tanenbaum Research Institute, Sinai Health, Toronto, Ontario, Canada $1 https://orcid.org/0000000244867496
- 700 1_
- $a Brennan, Paul $u Genomic Epidemiology Group, International Agency for Research on Cancer, Lyon, France $1 https://orcid.org/0000000205188714
- 700 1_
- $a Olshan, Andrew F $u University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA
- 700 1_
- $a Virani, Shama $u Genomic Epidemiology Group, International Agency for Research on Cancer, Lyon, France
- 700 1_
- $a Waterboer, Tim $u Infections and Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
- 773 0_
- $w MED00002298 $t International journal of cancer $x 1097-0215 $g Roč. 154, č. 2 (2024), s. 389-402
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37694289 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20240109 $b ABA008
- 991 __
- $a 20240213092945 $b ABA008
- 999 __
- $a ok $b bmc $g 2049032 $s 1209789
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 154 $c 2 $d 389-402 $e 20230911 $i 1097-0215 $m International journal of cancer $n Int J Cancer $x MED00002298
- GRA __
- $a R01 DE025712 $p NIDCR NIH HHS $2 United States
- GRA __
- $a P30CA047904 $p NIH HHS $2 United States
- GRA __
- $a P50CA097190 $p NIH HHS $2 United States
- GRA __
- $a R01 DE025712 $p NIDCR NIH HHS $2 United States
- GRA __
- $a P30CA047904 $p NIH HHS $2 United States
- GRA __
- $a P50CA097190 $p NIH HHS $2 United States
- LZP __
- $a Pubmed-20240109
